BioSpace News Archive

Panbela Therapeutics, Inc., is re-issuing this press release solely to correct an inadvertent decimal error in the net loss per share reported in the discussion under the heading “Fourth Quarter ended December 31, 2020 Financial Results.” All other data and disclosure remains unchanged.

Women’s History Month EmPOWERED to Serve™ roundtable focuses on challenges women continue to face in pursuit of health equity

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare, a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, announced it has earned a spot on the 2021 Report on Business Women Lead Here list, an annual editorial benchmark to identify best-in-class executive gender diversity in corporate Canada.

At virtual Annual General Shareholders’ Meeting, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the boards’ proposals by a large majority.

Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and Drug Administration has approved Abecma as the first B-cell maturation antigen -directed chimeric antigen receptor T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Enfortumab vedotin to be reviewed under accelerated assessment for the treatment of locally advanced or metastatic urothelial cancer

Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.